Unknown

Dataset Information

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre.


ABSTRACT:

Background

Trastuzumab deruxtecan (TDXd) is an antibody-drug conjugate that has demonstrated impressive activity in randomized controlled clinical trials in the context of patients with HER2-amplified and HER2-low metastatic breast cancer. We aimed to review the activity and adverse event profile of TDXd in heavily pretreated breast cancer patients in real practice.

Methods

We describe a single-center retrospective case series of metastatic breast cancer patients who were treated with TDXd. The outcomes of interest were the overall response rate, overall survival, progression-free survival and grade 4-5 adverse events. Objective responses and PFS were assessed in accordance with RECIST 1.1 criteria.

Results

We identified 38 patients treated with TDXd. Of these, 15 pat

SUBMITTER: Lazaratos AM 

PROVIDER: S-EPMC11763754 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature